Angiotensin II receptor blocker is the most prescribed category of anti-hypertensive pharmaceuticals worldwide, while OLMETEC PLUS® is a new-generation fixed-dose combination of an angiotensin II receptor blocker, olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide, and an exclusive production in the PRC pharmaceutical market.

Developed and manufactured by Daiichi Sankyo, commercialization and promotion in the Chinese market handled by Simcere.